Skip to main content
OpenTrials

Clinical trial condition

Hemophilia A

Explore clinical trials studying Hemophilia A. Study availability and eligibility vary by location and protocol.

600 public trials 74 recruiting studies
Refine in advanced search Browse all conditions

Hemophilia A trial results

Completed

Study of Biostate® in Children With Hemophilia A

NCT01229007

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +6 more
Locations
  • Study site Homyel, Belarus
  • Study site Minsk, Belarus
  • Study Site Tbilisi, Georgia
  • Study Site Guatemala City, Guatemala
View Trial Details
Completed

Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015

NCT00984126

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +8 more
Locations
  • Novo Nordisk Investigational Site Phoenix, Arizona, United States
  • Novo Nordisk Investigational Site Long Beach, California, United States
  • Novo Nordisk Investigational Site Tampa, Florida, United States
  • Novo Nordisk Investigational Site Atlanta, Georgia, United States
View all 57 locations
View Trial Details
Completed

Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects

NCT02490787

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +8 more
Locations
  • Novo Nordisk Investigational Site Torrance, California, United States
  • Novo Nordisk Investigational Site Indianapolis, Indiana, United States
  • Novo Nordisk Investigational Site Iowa City, Iowa, United States
  • Novo Nordisk Investigational Site Baltimore, Maryland, United States
View all 34 locations
View Trial Details
Completed

A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment

NCT02476942

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +6 more
Locations
  • Santa Monica Oncology Center Santa Monica, California, United States
  • University of Colorado Denver, Children's Hospital Aurora, Colorado, United States
  • Georgetown Uni Medical Center; Lombardi Cancer Center Washington D.C., District of Columbia, United States
  • Winship Cancer Institute Atlanta, Georgia, United States
View all 35 locations
View Trial Details
Completed

Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia

NCT01439971

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +6 more
Locations
  • University of California San Diego Medical Center San Diego, California, United States
  • New Haven Clinical Research Unit New Haven, Connecticut, United States
  • Rush University Medical Center Chicago, Illinois, United States
  • Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States
View all 23 locations
View Trial Details
Completed

Inhibitor Development in Patients With Hemophilia A Undergoing Surgery

NCT01571934

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +6 more
Locations
  • University of Colorado, Hemophilia and Thrombosis Center Aurora, Colorado, United States
  • Emory University Comprehensive Hemophilia Treatment Center Atlanta, Georgia, United States
  • Indiana Hemophilia and Thrombosis Center Indianapolis, Indiana, United States
  • University of North Carolina Chapel Hill, North Carolina, United States
View Trial Details
Completed

PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A

NCT02492984

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +6 more
Locations
  • The Affiliated Hospital of Guizhou Medical University Guiyang, Guizhou, China
  • Henan Provincial People's Hospital Zhengzhou, Henan, China
  • Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology Wuhan, Hubei, China
  • Department of Hematology,The First Affiliated Hospital of Soochow University Suzhou, Jiangsu, China
View all 15 locations
View Trial Details
Completed

Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A

NCT01138501

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +8 more
Locations
  • Novo Nordisk Investigational Site Phoenix, Arizona, United States
  • Novo Nordisk Investigational Site Orange, California, United States
  • Novo Nordisk Investigational Site Torrance, California, United States
  • Novo Nordisk Investigational Site Tampa, Florida, United States
View all 38 locations
View Trial Details
Completed

Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects

NCT00840086

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +8 more
Locations
  • Novo Nordisk Investigational Site Little Rock, Arkansas, United States
  • Novo Nordisk Investigational Site Long Beach, California, United States
  • Novo Nordisk Investigational Site Tampa, Florida, United States
  • Novo Nordisk Investigational Site Atlanta, Georgia, United States
View all 63 locations
View Trial Details

Related conditions